Ignyta, Inc., a precision oncology biotechnology company, engages in discovering, in-licensing or acquiring, developing, and commercializing molecularly targeted therapies for eradicating residual diseases. Its products pipeline includes entrectinib, a tyrosine kinase inhibitor directed to the Trk family tyrosine kinase receptors, ROS1, and ALK proteins, which is in Phase II and two Phase I clinical studies in molecularly defined adult patient populations for the treatment of solid tumors, as well as in Phase I/Ib clinical study in pediatric patients with advanced solid tumor malignancies; RXDX-105, a multikinase inhibitor targets as RET and BRAF that is in Phase I/Ib dose escalation clinical trial; and RXDX-106, a pseudo-irreversible inhibitor, which is in late preclinical development. The company was founded in 2011 and is headquartered in San Diego, California.